Theravance Q4 2020 Earnings Report

Reported financial results for the fourth quarter and full year ended December 31, 2020.

Key Takeaways

Theravance Biopharma reported its Q4 and full year 2020 financial results, highlighting a critical year of growth for YUPELRI despite the respiratory pandemic. The company is focused on delivering clinical development milestones for ampreloxetine and izencitinib in 2021.

YUPELRI experienced growth with increased market share despite the respiratory pandemic.

Clinical development milestones for ampreloxetine and izencitinib are a focus for 2021.

Initial clinical data from a TD-0903 study in patients hospitalized with acute lung injury due to COVID-19 showed positive trends.

Phase 2 study of TD-0903 is progressing, with data from Part 2 expected in Q2 2021.

Total Revenue

$18.7M

Previous year: $29.5M

-36.5%

EPS

-$0.92

Previous year: -$1.17

-21.4%